157 related articles for article (PubMed ID: 15688619)
1. New drugs from the sea.
D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
[TBL] [Abstract][Full Text] [Related]
2. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
Allavena P; Signorelli M; Chieppa M; Erba E; Bianchi G; Marchesi F; Olimpio CO; Bonardi C; Garbi A; Lissoni A; de Braud F; Jimeno J; D'Incalci M
Cancer Res; 2005 Apr; 65(7):2964-71. PubMed ID: 15805300
[TBL] [Abstract][Full Text] [Related]
4. Unique features of the mode of action of ET-743.
D'Incalci M; Erba E; Damia G; Galliera E; Carrassa L; Marchini S; Mantovani R; Tognon G; Fruscio R; Jimeno J; Faircloth GT
Oncologist; 2002; 7(3):210-6. PubMed ID: 12065793
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
Wright BJ; Chan C; Danishefsky SJ
J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
[TBL] [Abstract][Full Text] [Related]
6. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
8. Marine natural products as anticancer drugs.
Simmons TL; Andrianasolo E; McPhail K; Flatt P; Gerwick WH
Mol Cancer Ther; 2005 Feb; 4(2):333-42. PubMed ID: 15713904
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
10. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
11. Progress in the development and acquisition of anticancer agents from marine sources.
Amador ML; Jimeno J; Paz-Ares L; Cortes-Funes H; Hidalgo M
Ann Oncol; 2003 Nov; 14(11):1607-15. PubMed ID: 14581267
[No Abstract] [Full Text] [Related]
12. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
13. Progress in the clinical development of new marine-derived anticancer compounds.
Jimeno J; López-Martín JA; Ruiz-Casado A; Izquierdo MA; Scheuer PJ; Rinehart K
Anticancer Drugs; 2004 Apr; 15(4):321-9. PubMed ID: 15057135
[TBL] [Abstract][Full Text] [Related]
14. Ecteinascidin-743.
Held-Warmkessel J
Clin J Oncol Nurs; 2003; 7(3):313-9. PubMed ID: 12793338
[TBL] [Abstract][Full Text] [Related]
15. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.
Tognon G; Frapolli R; Zaffaroni M; Erba E; Zucchetti M; Faircloth GT; D'Incalci M
Cancer Chemother Pharmacol; 2004 Jan; 53(1):89-90. PubMed ID: 14586558
[No Abstract] [Full Text] [Related]
16. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
18. Sea squirt assaults sarcomas.
Burton A
Lancet Oncol; 2002 Nov; 3(11):648. PubMed ID: 12424055
[No Abstract] [Full Text] [Related]
19. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
20. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
